2024
Fever Prevention in Patients With Acute Vascular Brain Injury
Greer D, Helbok R, Badjatia N, Ko S, Guanci M, Sheth K, Diringer M, Mehta Y, Cava L, Hinduja A, Lele A, Sarwal A, Kulik T, Keller E, Smith G, Dennesen P, Dimitriadis K, Schonenberger S, Gunther A, Meisel A, Wolf S, Kollmar R, Barlinn K, Jeon S, Han M, Hong J, Lee R, Falcone G, Dashti S, Busl K, Ermak D, Berkeley J, Amory C, Swor R, DeGeorgia M, Green-LaRoche D, Thompson B, Hatton K, Sung G, Mehta C, Zurasky J, Da Silva I, James M, Aysenne A, Cervantes A, Devlin T, Chang I, Morris N, Venkatasubramanian C, Mushlschlegel S, Zachariah J, Chaudry F, Claassen J, Dangayach N, Choi H, Sadaka F, Miller C. Fever Prevention in Patients With Acute Vascular Brain Injury. JAMA 2024, 332: 1525-1534. PMID: 39320879, PMCID: PMC11425189, DOI: 10.1001/jama.2024.14745.Peer-Reviewed Original ResearchVascular brain injuryStandard care groupCare groupMajor adverse eventsPrimary outcomeStandard care patientsBlinded outcome assessmentIntensive care unit dischargeFunctional outcomesAdverse eventsBrain injuryFever preventionFever burdenPrincipal secondary end pointBetween-group differencesOpen-label randomized clinical trialPrevention groupFunctional recoveryPrincipal secondary outcomeCare patientsAssociated with worse outcomesMain OutcomesImpact functional outcomesSecondary end pointsTemperature management deviceDoor-in-Door-Out Times at Referring Hospitals and Outcomes of Hemorrhagic Stroke
Royan R, Ayodele I, Stamm B, Alhanti B, Sheth K, Pruitt P, Mac Grory B, Meurer W, Prabhakaran S. Door-in-Door-Out Times at Referring Hospitals and Outcomes of Hemorrhagic Stroke. Annals Of Emergency Medicine 2024 PMID: 39453306, DOI: 10.1016/j.annemergmed.2024.09.002.Peer-Reviewed Original ResearchDoor-in-door-out timeDoor-in-door-outAssociated with greater oddsEmergency departmentHemorrhagic strokeGreater oddsUnadjusted analysisGuidelines-Stroke participating hospitalsInhospital mortalityCare of patientsObservational cohort studyIntracerebral hemorrhageDIDO timeReceiving hospitalInterhospital transferIndependent ambulationRegistry dataSubarachnoid hemorrhageTime of transferCohort studySecondary outcomesEffect sizePrimary outcomeUS registry dataOddsSocioeconomic and medical determinants of state‐level subjective cognitive decline in the United States
de Havenon A, Stulberg E, Littig L, Wong K, Sarpong D, Li V, Sharma R, Falcone G, Williamson J, Pajewski N, Gottesman R, Brickman A, Sheth K. Socioeconomic and medical determinants of state‐level subjective cognitive decline in the United States. Alzheimer's & Dementia 2024, 20: 7567-7579. PMID: 39351858, PMCID: PMC11567845, DOI: 10.1002/alz.14220.Peer-Reviewed Original ResearchSubjective cognitive declinePrevalence of diabetesPrevalence of povertyMedical determinantsBehavioral Risk Factor Surveillance SystemRisk Factor Surveillance SystemCognitive declinePrevalence of subjective cognitive declineBurden of cognitive declinePopulation levelState-level prevalenceMedical risk factorsFunctional impairmentState-level associationsPhysician densityUnited StatesMedical factorsRates of povertyState-level analysisHousehold incomePrimary outcomeCollege educationSurveillance systemRisk factorsEthnic minoritiesDisability and Recurrent Stroke Among Participants in Stroke Prevention Trials
de Havenon A, Viscoli C, Kleindorfer D, Sucharew H, Delic A, Becker C, Robinson D, Yaghi S, Li V, Lansberg M, Cramer S, Mistry E, Sarpong D, Kasner S, Kernan W, Sheth K. Disability and Recurrent Stroke Among Participants in Stroke Prevention Trials. JAMA Network Open 2024, 7: e2423677. PMID: 39028666, PMCID: PMC11259901, DOI: 10.1001/jamanetworkopen.2024.23677.Peer-Reviewed Original ResearchConceptsPrevention trialsPoststroke disabilityRecurrent stroke ratesRecurrent strokeCohort studyRate of recurrent strokeStroke Prevention TrialIncreased hazardInsulin Resistance InterventionSecondary prevention trialsBaseline disabilityAssociated with increased ratesStroke rateMain OutcomesFunctional statusResistance InterventionStudy baselineSecondary outcomesPrimary outcomeWorsening heart failureModified Rankin ScaleProfession's participationLong-term followVascular deathDisabilityImpact of Procedure Time on First Pass Effect in Mechanical Thrombectomy for Anterior Circulation Acute Ischemic Stroke
Koo A, Reeves B, Renedo D, Maier I, Al Kasab S, Jabbour P, Kim J, Wolfe S, Rai A, Starke R, Psychogios M, Shaban A, Arthur A, Yoshimura S, Cuellar H, Grossberg J, Alawieh A, Romano D, Tanweer O, Mascitelli J, Fragata I, Polifka A, Osbun J, Crosa R, Park M, Levitt M, Brinjikji W, Moss M, Dumont T, Williamson R, Navia P, Kan P, Spiotta A, Sheth K, de Havenon A, Matouk C. Impact of Procedure Time on First Pass Effect in Mechanical Thrombectomy for Anterior Circulation Acute Ischemic Stroke. Neurosurgery 2024, 95: 128-136. PMID: 38483158, DOI: 10.1227/neu.0000000000002900.Peer-Reviewed Original ResearchAnterior circulation large vessel occlusion acute ischemic strokeAcute ischemic strokeLarge vessel occlusion acute ischemic strokeProcedure timeMechanical thrombectomyExcellent reperfusionClinical benefitIschemic strokeAnterior circulation acute ischemic strokeSuccess of mechanical thrombectomyModified Rankin Scale scoreRankin Scale scoreLogistic regression modelsNo significant differencePrimary study exposuresPrimary outcomeFunctional outcomesPotential confoundersStudy exposureThrombectomy devicesScale scoreThrombectomyReperfusionPatientsSignificant difference
2023
Code ICH: A Call to Action
Li Q, Yakhkind A, Alexandrov A, Alexandrov A, Anderson C, Dowlatshahi D, Frontera J, Hemphill J, Ganti L, Kellner C, May C, Morotti A, Parry-Jones A, Sheth K, Steiner T, Ziai W, Goldstein J, Mayer S. Code ICH: A Call to Action. Stroke 2023, 55: 494-505. PMID: 38099439, DOI: 10.1161/strokeaha.123.043033.Peer-Reviewed Original ResearchIntracerebral hemorrhageHematoma expansionNeurological outcomeEarly aggressive careAcute ischemic strokeBlood pressure controlPoor functional outcomeMultiple simultaneous interventionsBundled careAggressive careIschemic strokeIndependent predictorsPrimary outcomeAcute phaseEmergency reversalFunctional recoveryRandomized trialsFunctional outcomeWorse outcomesConsensus statementCurrent evidenceTreatment opportunitiesSingle interventionEarly interventionPressure controlEffects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials
Salman R, Stephen J, Tierney J, Lewis S, Newby D, Parry-Jones A, White P, Connolly S, Benavente O, Dowlatshahi D, Cordonnier C, Viscoli C, Sheth K, Kamel H, Veltkamp R, Larsen K, Hofmeijer J, Kerkhoff H, Schreuder F, Shoamanesh A, Klijn C, van der Worp H, Haemorrhage C, Klug D, Casolla B, Puy L, Coffee M, Kuchcinski G, Labreuche J, van Nieuwenhuizen K, Algra A, van Gelder I, Kappelle L, Rinkel G, Schutgens R, Khatri P, Conwit R, Falcone G, Elm J, Anderson C, Song L, Pandian J, Hart R, Sharma M, Aref H, Tarhuni W, Fabregas J, Diener H, Endres M, Lemmens R, Kwon S, Lee B, Ameriso S, Milling T, Kasner S, Mikulik R, Xavier D, Beer R, Toni D, Eckstein J, Seiffge D, Ferro J, Tsivgoulis G, Sharma S, Wei-Liou C, Hohnloser S, Katsanos A, Bosch J, Healey J, Eikelboom J, Khaw A, Gladstone D, Pikula A, Coutts S, Smith E, Butcher K, Field T, Gioia L, Stapf C, Halse O, Ringleb P, Enzinger C, Sibon I, Montaner J, Caso V, Heuschmann P, Lip G, Haefeli W, Debette S, Dennis M, Wyller T, Rønning O, Eilertsen H, Ihle-Hansen H, Sandset E, Pennlert J, Glader E, Kruuse C, Wester P, Carlsson M, Forfang E. Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials. The Lancet Neurology 2023, 22: 1140-1149. PMID: 37839434, DOI: 10.1016/s1474-4422(23)00315-0.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsAdverse cardiovascular eventsSpontaneous intracranial hemorrhageOral anticoagulationCardiovascular eventsIntracranial hemorrhageAtrial fibrillationCardiovascular deathIndividual participant dataEligible trialsHazard ratioPrimary outcomeOngoing trialsFixed-effect inverse variance modelParticipant dataDirect oral anticoagulantsOral anticoagulant agentsCochrane systematic reviewCox regression modelPrevious intracranial hemorrhageInverse variance modelBritish Heart FoundationLong-term useSubgroup of participantsAntiplatelet monotherapyImprovement in the Prediction of Cerebrovascular Events With White Matter Hyperintensity
de Havenon A, Smith E, Sharma R, Falcone G, Bangad A, Prabhakaran S, Sheth K. Improvement in the Prediction of Cerebrovascular Events With White Matter Hyperintensity. Journal Of The American Heart Association 2023, 12: e029374. PMID: 37345754, PMCID: PMC10356061, DOI: 10.1161/jaha.123.029374.Peer-Reviewed Original ResearchConceptsWhite matter hyperintensitiesIncident strokePrimary outcomeHypertensive individualsMatter hyperintensitiesAtherosclerotic cardiovascular disease risk scoreCognitive impairmentCardiovascular disease risk scoreVascular risk factorsCurrent cigarette smokingDisease risk scoreMagnetic resonance imagingLogistic regression modelsRandomization armCerebrovascular eventsVascular riskCigarette smokingPrognostic informationRisk factorsPrognostic abilityRisk scoreCognitive declineResonance imagingDeLong testStrokeChange in Smoking Behavior and Outcome After Ischemic Stroke: Post-Hoc Analysis of the SPS3 Trial
Anadani M, Turan T, Yaghi S, Spiotta A, Gory B, Sharma R, Sheth K, de Havenon A. Change in Smoking Behavior and Outcome After Ischemic Stroke: Post-Hoc Analysis of the SPS3 Trial. Stroke 2023, 54: 921-927. PMID: 36876480, PMCID: PMC10050138, DOI: 10.1161/strokeaha.121.038202.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsAdverse cardiovascular eventsAcute ischemic strokeIschemic strokeCardiovascular eventsPersistent smokersPersistent smokingSPS3 trialSmoking statusMyocardial infarctionMajor adverse cardiovascular events outcomesCardiovascular event outcomesMajor cardiovascular outcomesSubsequent cardiovascular eventsHistory of hypertensionRisk of strokeEnd of studyPost Hoc AnalysisPrior smokersRandomization armCardiovascular outcomesFormer smokersMonth 3Primary outcomeTotal cohortEmergent external ventricular drain placement in patients with factor Xa inhibitor-associated intracerebral hemorrhage after reversal with andexanet alfa
Ammar A, Elsamadicy A, Ammar M, Reeves B, Koo A, Falcone G, Hwang D, Petersen N, Kim J, Beekman R, Prust M, Magid-Bernstein J, Acosta J, Herbert R, Sheth K, Matouk C, Gilmore E. Emergent external ventricular drain placement in patients with factor Xa inhibitor-associated intracerebral hemorrhage after reversal with andexanet alfa. Clinical Neurology And Neurosurgery 2023, 226: 107621. PMID: 36791588, DOI: 10.1016/j.clineuro.2023.107621.Peer-Reviewed Original ResearchConceptsAndexanet alfaExtra-axial hemorrhageEVD placementThrombotic eventsNew hemorrhagePrimary safety outcomeExternal ventricular drain placementLarge prospective studiesIntensive care unitIntracerebral hemorrhage patientsVentricular drain placementBolus patientsHospital lengthHospital LOSICU LOSTract hemorrhageRankin scoreSecondary outcomesAdult patientsBolus groupPrimary outcomeCare unitIntracerebral hemorrhageLong administration timeHemorrhage patients
2022
Technical Dissonance in Home Blood Pressure Monitoring After Stroke: Having the Machine, but Not Using Correctly.
Forman R, Viscoli C, Meurer K, Sheth K, Sansing L, de Havenon A, Sharma R, Mariscal M, Kernan W. Technical Dissonance in Home Blood Pressure Monitoring After Stroke: Having the Machine, but Not Using Correctly. American Journal Of Hypertension 2022, 36: 195-200. PMID: 36520024, PMCID: PMC10016067, DOI: 10.1093/ajh/hpac129.Peer-Reviewed Original ResearchConceptsHome blood pressure monitoringBlood pressure monitoringBlood pressurePressure monitoringNon-Hispanic white patientsProportion of patientsCross-sectional studyNon-Hispanic white participantsStroke recurrenceRate of useMost patientsPrimary outcomeWhite patientsRate of possessionPatientsUnderrepresented patientsArm cuffHypertensionStrokeCorrect useWhite participantsSignificant disparitiesEthnic groupsParticipantsQuality of technique
2019
Surgical Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) Procedure
Awad I, Polster S, Carrión-Penagos J, Thompson R, Cao Y, Stadnik A, Money P, Fam M, Koskimäki J, Girard R, Lane K, McBee N, Ziai W, Hao Y, Dodd R, Carlson A, Camarata P, Caron J, Harrigan M, Gregson B, Mendelow A, Zuccarello M, Hanley D, Abdul-Rahim A, Abou-Hamden A, Abraham M, Ahmed A, Alba C, Aldrich E, Ali H, Altschul D, Amin-Hanjani S, Anderson C, Anderson D, Ansari S, Antezana D, Ardelt A, Arikan F, Avadhani R, Baguena M, Baker A, Barrer S, Barzo P, Becker K, Bergman T, Betz J, Bistran-Hall A, Boström A, Braun J, Brindley P, Broaddus W, Brown R, Buki A, Bulters D, Cao B, Carhuapoma J, Chalela J, Chang T, Chicoine M, Chorro I, Chowdhry S, Cobb C, Corral L, Csiba L, Davies J, Dawson J, Díaz A, Dierdeyn C, Diringer M, Dlugash R, Ecker R, Economas T, Enriquez P, Ezer E, Fan Y, Feng H, Franz D, Freeman W, Fusco M, Galicich W, Gandhi D, Gelea M, Goldstein J, Gonzalez A, Grabarits C, Greenberg S, Gregson B, Gress D, Gu E, Gupta G, Hall C, Harnof S, Hernandez F, Hoesch R, Hoh B, Houser J, Hu R, Huang J, Huang Y, Hussain M, Insinga S, Jadhav A, Jaffe J, Jahromi B, Jallo J, James M, James R, Janis S, Jankowitz B, Jeon E, Jichici D, Jonczak K, Jonker B, Karlen N, Kase C, Keric N, Kerz T, Kitagawa R, Knopman J, Koenig C, Krishnamurthy S, Kumar A, Kureshi I, Laidlaw J, Lakhanpal A, Latorre J, LeDoux D, Lees K, Leifer D, Leiphart J, Lenington S, Li Y, Lopez G, Lovick D, Lumenta C, Luo J, Maas M, MacDonald J, MacKenzie L, Madan V, Majkowski R, Major O, Malhorta R, Malkoff M, Mangat H, Maswadeh A, Matouk C, Mayo S, McArthur K, McCaul S, Medow J, Mezey G, Mighty J, Miller D, Mitchell P, Mohan K, Mould W, Muir K, Muñoz L, Nakaji P, Nee A, Nekoovaght-Tak S, Nyquist P, O'Kane R, Okasha M, O'Kelly C, Ostapkovich N, Pandey A, Parry-Jones A, Patel H, Perla K, Pollack A, Pouratian N, Quinn T, Rajajee V, Reddy K, Rehman M, Reimer R, Rincon F, Rosenblum M, Rybinnik I, Sanchez B, Sansing L, Sarabia R, Schneck M, Schuerer L, Schul D, Schweitzer J, Seder D, Seyfried D, Sheth K, Spiotta A, Stechison M, Sugar E, Szabo K, Tamayo G, Tanczos K, Taussky P, Teitelbaum J, Terry J, Testai F, Thomas K, Thompson C, Thompson G, Torner J, Tran H, Tucker K, Ullman N, Ungar L, Unterberg A, Varelas P, Vargas N, Vatter H, Venkatasubramanian C, Vermillion K, Vespa P, Vollmer D, Wang W, Wang Y, Wang Y, Wen J, Whitworth L, Willis B, Wilson A, Wolfe S, Wrencher M, Wright S, Xu Y, Yanase L, Yenokyan G, Yi X, Yu Z, Zomorodi A. Surgical Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) Procedure. Neurosurgery 2019, 84: nyz077-. PMID: 30891610, PMCID: PMC6537634, DOI: 10.1093/neuros/nyz077.Peer-Reviewed Original ResearchConceptsRecombinant tissue plasminogen activatorTissue plasminogen activatorICH volumeImproved mortalityIntracerebral hemorrhageFunctional outcomePlasminogen activatorFunctional outcome benefitsInitial hematoma volumeHistory of hypertensionBenefits of surgeryType of strokeDisease severity factorsSurgical performanceVolume reductionAlteplase dosesMRS 0Mortality benefitPrimary outcomeHematoma evacuationCatheter aspirationHematoma volumeICH evacuationOutcome benefitsSurgical armDeferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial
Selim M, Foster L, Moy C, Xi G, Hill M, Morgenstern L, Greenberg S, James M, Singh V, Clark W, Norton C, Palesch Y, Yeatts S, Investigators I, Dolan M, Yeh E, Sheth K, Kunze K, Muehlschlegel S, Nieto I, Claassen J, Falo C, Huang D, Beckwith A, Messe S, Yates M, O'Phelan K, Escobar A, Becker K, Tanzi P, Gonzales N, Tremont C, Venkatasubramanian C, Thiessen R, Save S, Verrault S, Collard K, DeGeorgia M, Cwiklinski V, Thompson B, Wasilewski L, Andrews C, Burfeind R, Torbey M, Hamed M, Butcher K, Sivakumar L, Varelas N, Mays-Wilson K, Leira E, Olalde H, Silliman S, Calhoun R, Dangayach N, Renvill R, Malhotra R, Kordesch K, Lord A, Calahan T, Geocadin R, Parish M, Frey J, Harrigan M, Leifer D, Mathias R, Schneck M, Bernier T, Gonzales-Arias S, Elysee J, Lopez G, Volgi J, Brown R, Jasak S, Phillips S, Jarrett J, Gomes J, McBride M, Aldrich F, Aldrich C, Kornbluth J, Bettle M, Goldstein J, Tirrell G, Shaw Q, Jonczak K. Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. The Lancet Neurology 2019, 18: 428-438. PMID: 30898550, PMCID: PMC6494117, DOI: 10.1016/s1474-4422(19)30069-9.Peer-Reviewed Original ResearchConceptsBetter clinical outcomesPhase 2 trialSerious adverse eventsRankin Scale scorePlacebo groupIntracerebral hemorrhagePrimary outcomeClinical outcomesDay 90Deferoxamine mesylateModified intentionTreat populationAdverse eventsUS National InstitutesDouble-blind phase 2 trialScale scorePhase 3 efficacy trialsModified Rankin Scale scoreEfficacy of deferoxaminePhase 3 trialSupratentorial intracerebral hemorrhageAbsolute risk differenceProportion of participantsNational InstituteIron chelator deferoxamine